Podcast

Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)

Author(s):

Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.

Welcome to OncLive On Air®! I’m your host today, Jason Harris.

OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In the second of a two-part series, I sat down again with Narjust Duma, MD, a physician and associate director of the Cancer Equity Program at Dana-Farber Cancer Institute, and assistant professor of medicine at Harvard Medical School, to talk about the unique challenges facing women with lung cancer.

Although lung cancer is the second-leading cancer in women and the leading cause of cancer deaths, the danger of lung cancer is often overlooked. Moreover, women make up only 39% of participants in lung cancer clinical trials. Dr Duma said the lack of women in trials has major ramifications.

In our exclusive interview, Dr Duma discussed improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.

___

That’s all we have for today! Thanks again to my guest, Dr Narjust Duma, and you for listening to this episode of OncLive On Air®. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive® is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air®.

*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Related Videos
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study
Eric Winer, MD
Paolo Tarantino, MD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA
Benjamin Levy, MD
Lorlatinib vs Crizotinib in Treatment-Naive Patients With Advanced ALK+ Non-Small Cell Lung Cancer: 5-Year Progression-Free Survival and Safety From the CROWN Study
Chinmay Jani, MD, clinical fellow, Hematology & Oncology, Sylvester Comprehensive Cancer Center at the University of Miami/Jackson Memorial Hospital
Joaquim Bellmunt, MD, PhD
Lakshmi Nayak, MD